Application 203611
- Type
- ANDA
- Sponsor
- ACTAVIS ELIZABETH
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GABAPENTIN | GABAPENTIN | TABLET; ORAL | 300MG | No | No |
| 002 | GABAPENTIN | GABAPENTIN | TABLET; ORAL | 600MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203611-001 | GABAPENTIN | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | |
| A203611-002 | GABAPENTIN | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203611-001 | AB2 |
| A203611-002 | AB2 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203611-001 | AB2 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A203611-002 | AB2 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A203611-001 | AB2 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203611-002 | AB2 | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-001 | AB2 | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-002 | AB2 | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GABAPENTIN | GABAPENTIN | Proficient Rx LP | 92c4d589-533b-4fe4-833f-dd68cc1f7e66 | 2019-11-01 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 2ef99c3d-866a-438b-a340-8beba8d4c457 | 2019-11-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Proficient Rx LP | c78f528f-9192-4037-bfb9-ff5718ed26c5 | 2019-10-01 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Epic Pharma, LLC | 030e656a-e384-49ac-830f-32140c18112d | 2019-01-07 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | a900bafb-8f49-4a01-ba7f-4fb228ec0253 | 2018-11-12 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 6702ed8f-4aaf-46fa-bf39-db75154aa44c | 2018-10-19 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 1b73e9db-eddb-49ba-9778-01d39ece4d16 | 2018-09-21 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | f455b415-12a2-4916-b826-246976a8af44 | 2018-09-12 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 5fbd601f-df95-4a79-a7d3-c3505e23b913 | 2018-09-06 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 9d1b9121-c25a-4d28-91c5-5fc72f1167f4 | 2018-07-12 | GABAPENTIN GABAPENTIN | |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 37d4d465-19a5-46db-80dc-0b7334b3343a | 2018-06-25 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 6fc8e8b2-5d0e-4c72-9a46-6d312c3efac7 | 2018-05-14 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 86b30e64-fe56-42b3-a0f8-d9ef5d4b8c49 | 2016-06-20 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Bi-Coastal Pharma International LLC | e0cd96d1-b1ef-46ec-a5a3-9505b0811b8b | 2016-04-17 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.